key: cord-0833233-x7bvm52g
authors: Krishnan, Usha S.; Krishnan, Sankaran S.; Jain, Shipra; Chavolla-Calderon, Mara B.; Lewis, Matthew; Chung, Wendy K.; Rosenzweig., Erika B.
title: SARS-CoV-2 Infection in Patients with Down Syndrome, Congenital Heart Disease, and Pulmonary Hypertension: Is Down Syndrome a Risk Factor?
date: 2020-06-28
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.06.076
sha: 660c73b083de5a9733c1355e8916ebaa6912988d
doc_id: 833233
cord_uid: x7bvm52g

nan

With increasing information available about the epidemiology, pathophysiology and management of patients affected with SARS-CoV-2 infection, patients with Down syndrome, congenital heart disease, airway obstruction and pulmonary hypertension present a unique challenge. This case series describes three patients with Down syndrome and respiratory failure secondary to coronavirus infection.

Since severe acute respiratory syndrome associated with coronavirus 2 (SARS-CoV-2) infection was first described the disease has become a global pandemic and through May 2020, has affected over 3.6 million people worldwide and left over 251,000 dead. In the 4 months since it was first described, there has been increasing understanding about the epidemiology, populations at risk, pathophysiology, possible treatment opportunities and research into development of a vaccine.(1, 2) It has been observed that adults with pulmonary hypertension who otherwise have minimal cardiopulmonary reserve may not fare worse with SARS-CoV-2 than the general population.

(3,4) Another subgroup of patients, those with congenital heart disease (CHD), is a population being closely followed in several adult congenital heart disease registries. (5) We report three patients with Down syndrome and World Symposium of Pulmonary Hypertension Group 1 pulmonary hypertension associated with congenital heart disease who were hospitalized with SARS-CoV-2 illness in April 2020. They are unique in that a combination of Down syndrome, CHD, obstructive sleep apnea (OSA) and pulmonary hypertension as co-morbidities typically puts them at high risk during respiratory viral illnesses. Serum IL-6 levels, complete blood count, serum hepatic enzymes, troponins, ferritin, procalcitonin and pro BNP levels were normal. He was initially treated with antibiotics for urosepsis and also received 2 days of methylprednisone, azithromycin and hydroxychloroquine, which were terminated after 48 hours because of prolongation of QTc interval on electrocardiogram. Echocardiogram showed normal biventricular function with mild pulmonary hypertension. After 3 days of hospitalization, he developed mild hypotension and was obtunded, prompting further sepsis evaluation, escalation of antibiotics and increase in CPAP from 5 to 8 cm water. His baseline regimen of sildenafil 10 mg three times a day was continued. He has since recovered to baseline and is doing well at home.

6 A 25-year-old female with Down syndrome, unrepaired AVSD with Eisenmenger physiology and OSA, dependent on night CPAP, was previously followed as an outpatient and treated with sildenafil 40 mg three times a day. She had a telemedicine consultation, during which her parents reported that she had high fever, emesis, decreased urine output, and lethargy. She was assessed to be dehydrated, and was hospitalized for rehydration and further management. She The intensive care team used strategies for ARDS including prone ventilation with gradually improving ventilatory requirements. During hospitalization, he received a tracheostomy and has since been discharged home on tracheostomy collar by day and night time CPAP.

Patients with Down syndrome and CHD generally are considered at higher risk for developing viral infections and often have significantly increased morbidity and mortality. (5) (6) (7) (8) (9) In patients with adult congenital heart disease, those with unrepaired shunts and Eisenmenger physiology usually are at higher risk for developing more severe disease with viral infections such as SARS- Although information about the overall epidemiology and clinical characteristics of patients with congenital heart disease and SARS-CoV-2 infection is still emerging, patients with Down syndrome should continue to be considered in a high risk category. Their clinical presentation may be variable depending on the unique alterations to the immune system associated with Down syndrome.

Clinical Characteristics of Coronavirus Disease 2019 in China

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Could pulmonary arterial hypertension (PAH) patients be at a lower risk from severe COVID-19

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

Quantitative, Phenotypical, and Functional Characterization of Cellular Immunity in Children and Adolescents with Down Syndrome

Children with down syndrome are high-risk for severe respiratory syncytial virus disease

Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: A meta-analysis

IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome